In this week's podcast edition of Five Must-Know Things: Pfizer bullish on its oral glp-1; BMS’s rising confidence about Medicare pricing of Eliquis; more long term data for Leqembi; NewAmsterdam’s CETP inhibitor shows promise; and a look at Mankind’s Bharat Serums buy.  

The first Phase III trial testing the oral CETP inhibitor obicetrapib for the treatment of high cholesterol read out positively, years after some other drugs in the class failed.  

AstraZeneca is looking to speed AZD0780 into Phase III development after it achieved a 78% total LDL cholesterol reduction in a Phase I study when used in combination with rosuvastatin. The firm needs to play catch up with its oral rivals.

Public Company Edition: Fourth quarter 2023 fundraising fell 25.1% from Q4 2022, including a 24.2% drop in follow-on dollars, but recent activity has been robust, including $300m and $350m offerings by 4DMT and Autolus. Also, BMS sold $13bn in notes to fund Karuna and RayzeBio deals.